At a glance
ClinicalIndex Comparison Record- ✓Biopsy-proven prostate cancer with high-risk features: T1b/T1c/T2a with PSA >10 or Gleason ≥4+3=7 or PSA velocity >2.0 ng/ml/year; OR T2c/T3a/T3b/T4; OR Gleason ≥3+4=7 with ≥50% positive cores; OR any Gleason 5 tertiary component
- ✓Negative bone scan
- ✓Lymph node assessment by CT or MR imaging performed
- ✓ECOG performance status 0 or 1
- ✕Prior history of malignancy within 5 years, except in-situ cancers unlikely to affect life expectancy
- ✕Prior pelvic radiation therapy
- ✕Prior hormonal therapy, except if ≤4 weeks prior to enrollment
- ✕Unable to tolerate lying still for 5-10 minutes
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Docetaxel Plus 6-month Androgen Suppression and Radiation Therapy Versus 6-month Androgen Suppression and Radiation Therapy for Patients With High Risk Localized or Locally Advanced Prostate Cancer: A Randomized Controlled Trial
In Brief
A Phase 3 clinical trial evaluating Docetaxel, Androgen Hormonal Suppression and Radiation, and 1 other intervention for Prostate Cancer. Completed, enrolled 350 participants across 1 site.
Detailed Summary
This randomized study is looking at the benefits of using docetaxel (chemotherapy) added to one of the standard treatments (radiation and hormones) for men with high-risk prostate cancer.
Study Details
Timeline
Interventions
60 mg/m² q 3 weeks for 3 cycle at the start of treatment followed by weekly Docetaxel at 20 mg/m² per week beginning at week one of radiation therapy and continuing for seven weeks.
Total Androgen Ablation and external beam radiation therapy
Total Androgen Ablation and External Beam Radiation Therapy